Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus NivolumabYusuke Yano, Haruhito Azuma, Atsuhiko Yoshizawa et al.|Cancers|2022Cited by 21
Re‐challenging chemotherapy after pembrolizumab in platinum‐refractory urothelial carcinomaTaizo Uchimoto, Haruhito Azuma, Tatsuo Fukushima et al.|British Journal of Urology|2022Cited by 10
Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective StudyTakuhisa Nukaya, Ryoichi Shiroki, Kiyoshi Takahara et al.|Clinical Genitourinary Cancer|2023Cited by 8
Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survivalKeita Nakamori, Haruhito Azuma, Yoshio Ohno et al.|Clinical and Translational Radiation Oncology|2022Cited by 7